Researchers conducted a population-based, self-controlled risk interval study. They used linked universal health administrative data from a diverse population in Ontario, Canada. They performed two separate analyses of data from new varenicline users between Sept. 1, 2011, and Feb. 15, 2014, one year before to one year after receiving varenicline.
The study shows that among 56,851 new varenicline users, 6,317 cardiovascular and 10,041 neuropsychiatric hospitalizations and emergency department visits occurred from one year before to one year receiving varenicline.
The incidence of cardiovascular events was 34 percent higher in the 12 weeks following varenicline receipt (the risk interval) compared with the remaining observation period. The relative incidence of neuropsychiatric events was marginally significant in the primary analysis, but not all sensitivity analyses.
More articles on population health:
Heart disease patients without spouses at higher risk of dying
US government lifts ban on controversial virus research
Vaping ups likelihood of tobacco cigarette use in young adults
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
